Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vinati Organics Limited (VINATIORGA.NS)
Mumbai, IN
Vinati Organics Limited, established in Mumbai, India in 1989, operates as a specialty chemical enterprise specializing in the production and global distribution of organic intermediaries and monomers. While primarily serving the Indian market, the company also exports its diverse product range to key international regions including the United States, Europe, and various parts of Asia. Its extensive portfolio features a variety of specialty monomers, such as 2-acrylamido-2-methylpropane sulphonic acid (2-AMPS) and its sodium salt, alongside N-tertiary butyl acrylamide (NTBA) and N-tertiary octyl acrylamide (NTOA). The company is also a significant producer of aromatic compounds. These include isobutyl benzene, a critical precursor for manufacturing ibuprofen, an anti-inflammatory analgesic drug; normal butyl benzene, utilized in the synthesis of numerous chemical intermediates; and hexenes, valued for applications like low-boiling point solvents, thinners, extraction agents, tire retreading, as octane boosters for gasoline, and in C5/C6 aliphatic petroleum. Butyl phenols are also part of this segment. Further expanding its chemical offerings, Vinati Organics provides methyl-4-tert butyl benzoate and para tertiary butyl benzoic acid. It manufactures isobutylene, a branched olefin; methanol, which functions as a chemical intermediate; and high-purity methyl tertiary butyl ether (MTBE), widely used as a solvent in organic and pharmaceutical synthesis, as well as in Grignard's reagent production. Tertiary-butylamine is another specialized chemical produced. Additionally, the firm develops polymers tailored for diverse industrial sectors, including construction, ceramics, oil drilling, mining, leather processing, and paper manufacturing.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.17% | +0.24% | +1.15% | -3.32% | -18.17% | -18.00% | -30.71% | -28.83% | -26.30% | +397.84% | +8,479.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-0.4% Q1'26: -5.1% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+9.5% Q1'26: +0.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+20.4% Q1'26: +38.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+26.7% ★ Q1'26: +26.5% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+15.0% ★ Q1'26: +16.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2011 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 7 EPS Ana. |
Mar 2027 5 Rev. Ana. 5 EPS Ana. |
Mar 2028 7 Rev. Ana. 7 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.23B
est: 3.13B (+3.2%)
|
6.96B
est: 7.15B (-2.6%)
|
7.72B
est: 7.78B (-0.8%)
|
6.31B
est: 6.22B (+1.4%)
|
6.26B
est: 6.63B (-5.6%)
|
7.31B
est: 7.33B (-0.4%)
|
11.08B
est: 11.04B (+0.3%)
|
10.11B
est: 10.62B (-4.9%)
|
9.42B
est: 9.46B (-0.4%)
|
16.13B
est: 15.24B (+5.8%)
|
20.65B
est: 21.21B (-2.6%)
|
18.90B
est: 18.29B (+3.3%)
|
22.36B
est: 22.45B (-0.4%)
|
22.32B
21.70B – 23.01B
-0.5% YoY
|
26.29B
25.66B – 27.18B
+17.8% YoY
|
30.59B
27.29B – 35.77B
+16.3% YoY
|
36.71B
34.13B – 40.68B
+20.0% YoY
|
| EBITDA |
760.75M
est: 964.92M (-21.2%)
|
1.52B
est: 4.51B (-66.3%)
|
1.96B
est: 5.21B (-62.3%)
|
2.08B
est: 3.89B (-46.4%)
|
2.29B
est: 2.14B (+6.9%)
|
2.30B
est: 2.52B (-8.7%)
|
4.54B
est: 3.72B (+22.1%)
|
4.59B
est: 4.41B (+4.1%)
|
3.78B
est: 4.91B (-23.0%)
|
4.95B
est: 6.45B (-23.3%)
|
6.24B
est: 7.35B (-15.2%)
|
5.09B
est: 8.94B (-43.1%)
|
6.25B
est: 6.59B (-5.1%)
|
6.48B
6.30B – 6.68B
-1.7% YoY
|
7.63B
7.45B – 7.89B
+17.8% YoY
|
8.88B
7.92B – 10.38B
+16.3% YoY
|
10.65B
9.91B – 11.81B
+20.0% YoY
|
| EBIT |
696.26M
est: 852.00M (-18.3%)
|
1.36B
est: 4.30B (-68.3%)
|
1.79B
est: 4.97B (-64.1%)
|
1.90B
est: 3.72B (-48.9%)
|
2.08B
est: 2.05B (+1.4%)
|
2.05B
est: 2.13B (-3.8%)
|
4.26B
est: 2.92B (+46.1%)
|
4.26B
est: 3.49B (+21.9%)
|
3.35B
est: 4.14B (-19.0%)
|
4.50B
est: 5.44B (-17.4%)
|
5.65B
est: 6.20B (-8.9%)
|
4.36B
est: 7.54B (-42.2%)
|
5.37B
est: 5.75B (-6.7%)
|
5.65B
5.50B – 5.83B
-1.7% YoY
|
6.66B
6.50B – 6.88B
+17.8% YoY
|
7.75B
6.91B – 9.06B
+16.3% YoY
|
9.30B
8.64B – 10.30B
+20.0% YoY
|
| Net Income |
519.69M
est: 528.72M (-1.7%)
|
861.55M
est: 3.01B (-71.3%)
|
1.16B
est: 3.48B (-66.7%)
|
1.32B
est: 2.60B (-49.3%)
|
1.40B
est: 1.43B (-2.0%)
|
1.44B
est: 1.50B (-4.0%)
|
2.82B
est: 2.20B (+28.6%)
|
3.34B
est: 2.60B (+28.2%)
|
2.69B
est: 3.59B (-25.0%)
|
3.47B
est: 4.72B (-26.5%)
|
4.19B
est: 5.37B (-22.0%)
|
3.23B
est: 6.53B (-50.6%)
|
4.05B
est: 4.13B (-2.0%)
|
4.44B
4.10B – 4.74B
+7.5% YoY
|
4.96B
4.76B – 5.44B
+11.7% YoY
|
5.84B
4.91B – 6.78B
+17.7% YoY
|
7.18B
6.53B – 8.19B
+23.0% YoY
|
| SGA |
196.10M
est: 160.67M (+22.1%)
|
574.62M
est: 819.92M (-29.9%)
|
318.99M
est: 947.98M (-66.4%)
|
358.91M
est: 708.44M (-49.3%)
|
419.87M
est: 390.26M (+7.6%)
|
491.61M
est: 664.48M (-26.0%)
|
543.48M
est: 1.14B (-52.5%)
|
644.14M
est: 832.82M (-22.7%)
|
728.04M
est: 1.10B (-33.9%)
|
841.54M
est: 1.45B (-41.8%)
|
1.00B
est: 1.65B (-39.2%)
|
1.19B
est: 2.00B (-40.5%)
|
1.40B
est: 1.44B (-2.9%)
|
1.42B
1.38B – 1.46B
-1.7% YoY
|
1.67B
1.63B – 1.72B
+17.8% YoY
|
1.94B
1.73B – 2.27B
+16.3% YoY
|
2.33B
2.17B – 2.58B
+20.0% YoY
|
| EPS |
5.26
est: 5.10 (+3.1%)
|
8.73
est: 8.79 (-0.7%)
|
11.43
est: 11.08 (+3.1%)
|
12.75
est: 11.23 (+13.5%)
|
13.60
est: 13.58 (+0.1%)
|
13.97
est: 13.85 (+0.9%)
|
27.48
est: 25.83 (+6.4%)
|
32.48
est: 31.31 (+3.7%)
|
26.20
est: 26.78 (-2.1%)
|
33.72
est: 32.93 (+2.4%)
|
40.43
est: 46.59 (-13.2%)
|
31.15
est: 32.66 (-4.6%)
|
39.09
est: 39.95 (-2.1%)
|
42.86
39.52 – 45.68
+7.3% YoY
|
47.87
45.92 – 52.49
+11.7% YoY
|
56.32
47.32 – 65.35
+17.7% YoY
|
69.25
62.94 – 78.99
+23.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B | 3/5 | 5/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-11 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-10 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-09 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-04 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-03 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-02 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-01 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vinati Saraf Mutreja | Chief Executive Officer, MD & Executive Director | 92M | female |
| Vinod Banwarilal Saraf | Founder & Executive Chairman | 28M | male |
| Viral Saraf Mittal | Director of CSR & Non-Independent Executive Director | 12M | female |
| Amit Thanawala | Chief Operating Officer & Whole Time Director | 5M | male |
| Milind A. Wagh | Company Secretary & Compliance Officer | — | male |
| Mahendra Kumar Churiwala | Senior Vice President of Marketing | — | male |
| Gulshan Kumar Sakhuja | Chief Financial Officer | — | male |
| Budhi Sagar Lathi | Executive President of Mahad Plant | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VINATIORGA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
